Bosulif (bosutinib)

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor

Related drugs:

‹

›

BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	bosutinib Sensitive: A1 - Approval bosutinib Sensitive : A1	bosutinib Sensitive: A1 - Approval bosutinib Sensitive : A1
BCR-ABL1 V299L	Chronic Myeloid Leukemia	BCR-ABL1 V299L	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2
BCR-ABL1 G250E	Chronic Myeloid Leukemia	BCR-ABL1 G250E	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 F317L	Chronic Myeloid Leukemia	BCR-ABL1 F317L	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 V299L	Acute Lymphocytic Leukemia	BCR-ABL1 V299L	Acute Lymphocytic Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 F317L	Acute Lymphocytic Leukemia	BCR-ABL1 F317L	Acute Lymphocytic Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 G250E	Acute Lymphocytic Leukemia	BCR-ABL1 G250E	Acute Lymphocytic Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	bosutinib + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria bosutinib + inotuzumab ozogamicin Sensitive : C2	bosutinib + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria bosutinib + inotuzumab ozogamicin Sensitive : C2
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	venetoclax + bosutinib Sensitive: C3 – Early Trials venetoclax + bosutinib Sensitive : C3	venetoclax + bosutinib Sensitive: C3 – Early Trials venetoclax + bosutinib Sensitive : C3
BCR-ABL1 L248V	Chronic Myeloid Leukemia	BCR-ABL1 L248V	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 E255V	Chronic Myeloid Leukemia	BCR-ABL1 E255V	Chronic Myeloid Leukemia	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3
BCR-ABL1 M351T	Chronic Myeloid Leukemia	BCR-ABL1 M351T	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 F359I	Chronic Myeloid Leukemia	BCR-ABL1 F359I	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 F359V	Chronic Myeloid Leukemia	BCR-ABL1 F359V	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 Y253H	Chronic Myeloid Leukemia	BCR-ABL1 Y253H	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 E255K	Chronic Myeloid Leukemia	BCR-ABL1 E255K	Chronic Myeloid Leukemia	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3
BCR-ABL1 I432T	Chronic Myeloid Leukemia	BCR-ABL1 I432T	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 C475V	Chronic Myeloid Leukemia	BCR-ABL1 C475V	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 L387F	Chronic Myeloid Leukemia	BCR-ABL1 L387F	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 Q300R	Chronic Myeloid Leukemia	BCR-ABL1 Q300R	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 H396R	Chronic Myeloid Leukemia	BCR-ABL1 H396R	Chronic Myeloid Leukemia	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3
BCR-ABL1 F359C	Chronic Myeloid Leukemia	BCR-ABL1 F359C	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 N336S	Chronic Myeloid Leukemia	BCR-ABL1 N336S	Chronic Myeloid Leukemia	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3
BCR-ABL1 E453A	Chronic Myeloid Leukemia	BCR-ABL1 E453A	Chronic Myeloid Leukemia	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3	bosutinib Resistant: C3 – Early Trials bosutinib Resistant : C3
BCR-ABL1 M244V	Chronic Myeloid Leukemia	BCR-ABL1 M244V	Chronic Myeloid Leukemia	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib + bosutinib Sensitive: C3 – Early Trials palbociclib + bosutinib Sensitive : C3	palbociclib + bosutinib Sensitive: C3 – Early Trials palbociclib + bosutinib Sensitive : C3
IDH2 mutation + NPM1 mutation	Acute Myelogenous Leukemia	IDH2 mutation + NPM1 mutation	Acute Myelogenous Leukemia	bosutinib Sensitive: C4 – Case Studies bosutinib Sensitive : C4	bosutinib Sensitive: C4 – Case Studies bosutinib Sensitive : C4

Bosulif (bosutinib)

Associations
(46)

Associations
(46)

Bosulif (bosutinib)

Associations(46)

Associations(46)

Associations
(46)

Associations
(46)